Sage Represents Mateon Therapeutics - Leadershp in Novel Vascular Targeted Therapy

Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology indications. The company has two VDAs in clinical development, CA4P and OXi4503, the lead one of which is being studied in a phase 2/3 clinical trial in platinum resistant ovarian cancer. Read More ...
Posted on 28 Dec 2016

Opportunity to License or Acquire ES-3000, An Orphan Drug for CML and AML

Escend Therapeutics ( is based in San Diego, CA, and develops small molecule therapeutics for oncology orphan drug indications. ES-3000 is an orally bioavailable small molecule (FW ~600 Da) with a unique mechanism of action and established clinical safety. Read More ...
Posted on 28 Nov 2016